

Figure S1. SHAP values and feature interaction scores in logistic regression-based prediction. (A) The most important features for the prediction of chemotherapy-associated adverse effects (ranked from most to least important). (B) The distribution of the impacts of each of the most important features on model output. SHAP, Shapley Additive Explanation; WBC, white blood cell; PLT, platelet; ToP, total protein; Hb, hemoglobin; HTN, hypertension; rhG-CSF, recombinant-human granulocyte colony stimulating factor; EP, etoposide/cisplatin; Tumor Hx, tumor history; DL, docetaxel/lobaplatin; Non-comp, non-complete; EL, etoposide/lobaplatin; ALB, albumin; BMI, body mass index; LYM, lymphocytes; ALT, alanine aminotransferase; DP, docetaxel/cisplatin; POX, pemetrexed/oxaliplatin; PL, pemetrexed/lobaplatin; TP, paclitaxel/cisplatin.




Figure S2. SHAP values and feature interaction scores in AdaBoost-based prediction. (A) The most important features for the prediction of chemotherapy-associated adverse effects (ranked from most to least important). (B) The distribution of the impacts of each of the most important features on model output. SHAP, Shapley Additive Explanation; WBC, white blood cell; PLT, platelet; ToP, total protein; Hb, hemoglobin; HTN, hypertension; rhG-CSF, recombinant-human granulocyte colony stimulating factor; EP, etoposide/cisplatin; Tumor Hx, tumor history; DL, docetaxel/lobaplatin; Non-comp, non-complete; EL, etoposide/lobaplatin; ALB, albumin; BMI, body mass index; Lym, lymphocytes; ALT, alanine aminotransferase; DP, docetaxel/cisplatin; POX, pemetrexed/oxaliplatin; PL, pemetrexed/lobaplatin; TP, paclitaxel/cisplatin.




Figure S3. SHAP values and feature interaction scores in multi-layer perceptron-based prediction. (A) The most important features for the prediction of chemo-associated adverse effects (ranked from most to least important). (B) The distribution of the impacts of each of the most important features on model output. SHAP, Shapley Additive Explanation; WBC, white blood cell; PLT, platelet; ToP, total protein; Hb, hemoglobin; HTN, hypertension; rhG-CSF, recombinant-human granulocyte colony stimulating factor; EP, etoposide/cisplatin; Tumor Hx, tumor history; DL, docetaxel/lobaplatin; Non-comp, non-complete; EL, etoposide/lobaplatin; ALB, albumin; BMI, body mass index; Lym, lymphocytes; ALT, alanine aminotransferase; DP, docetaxel/cisplatin; POX, pemetrexed/oxaliplatin; PL, pemetrexed/lobaplatin; TP, paclitaxel/cisplatin.

